CheckMate 8HW: Nivolumab Plus Ipilimumab for MSI-H/dMMR Metastatic Colorectal Cancer
By Thierry André, MD - Last Updated: January 31, 2025Dr. Thierry André, head of the Medical Oncology Department at Hôpital Saint Antoine, discusses the CheckMate 8HW study presented at ASCO GI 2025 on nivolumab plus ipilimumab versus nivolumab monotherapy in MSI-H/dMMR metastatic colorectal cancer.
Advertisement
Dr. André elaborates on the efficacy and safety profiles of both treatments, and how the results of the study influence the current treatment landscape for patients with this disease.
Advertisement
Related Posts
Dr. Christopher Lieu shares his top liver-directed therapies for metastatic colorectal cancer with liver involvement.
Dr. Christopher Lieu shares his list of top targeted therapies for metastatic colorectal cancer.
The DYNAMIC study began in 2015 to analyze the efficacy of ctDNA in guiding the use of adjuvant chemotherapy.
Dr. Alan Venook reflects on how his leadership roles have shaped his collaborative approach to cancer research and treatment.
Sotorasib plus panitumumab may prolong progression-free survival in patients with KRAS G12C mCRC.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.